Shows

Medicinal Cannabis reform: Patient demand vs regulatory hurdles in Australia

Industry experts discuss medicinal cannabis regulations and proposed reforms to improve patient access and public safety in Australia

Published

4 months ago

February 16, 2026

Harvey Vargas

Cannabiz in Conversation discusses Australia’s medicinal cannabis reform amid rising demand and regulatory challenges, featuring Martin Lane and other experts

In Short:
– Cannabiz in Conversation discusses Australia’s medicinal cannabis reform amid rising demand and regulatory challenges.
– Key participants include Teresa Nicoletti, Dr. Priya Ayya, Martin Lane, and Professor Nicholas Lintzeris.

In this episode of Cannabiz in Conversation, we explore the ongoing debate around medicinal cannabis reform in Australia.

Hosted by Ahron Young, the discussion features Teresa Nicoletti from the Australian Medicinal Cannabis Association (AMCA), Professor Nicholas Lintzeris from the University of Sydney, Martin Lane from Cannabiz, and Dr Priya Ayyar from Releaf Clinics.

Medicinal cannabis use has exceeded early projections, putting pressure on the regulatory system. Patients with chronic conditions must navigate the TGA’s Special Access Scheme B (SASB) to access treatment, while doctors face administrative hurdles. Concerns about misuse are raised, but most prescriptions are genuinely for medical purposes rather than recreational use.

Proposed reforms aim to improve patient access while maintaining safety, product quality, and prescriber education. Overly strict restrictions could push patients toward the black market, while thoughtful reform could position Australia as a global leader in medicinal cannabis access.